search
Back to results

Hysterectomy and OPPortunistic SAlpingectomy (HOPPSA)

Primary Purpose

Ovarian Cancer, Complication

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Salpingectomy
Sponsored by
Göteborg University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ovarian Cancer focused on measuring Salpingectomy, Hysterectomy, Ovarian cancer

Eligibility Criteria

20 Years - 54 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Planned hysterectomy for a benign reason
  • Age < 55 years at randomization
  • Willing to be randomized
  • Vaginal route may be included if the surgeon is confident with performing vaginal salpingectomy.

Exclusion Criteria:

  • Previous bilateral oophorectomy and/or salpingectomy
  • Planned oophorectomy and/or salpingectomy (for reasons such as already diagnosed adnexal tumor, known carrier of the breast cancer susceptibility gene (BRCA) 1/2 mutation or Lynch syndrome (hereditary nonpolyposis colorectal cancer))
  • Non-understanding of the oral or written study information

Sites / Locations

  • Sahlgrenska University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Salpingectomy

No salpingectomy

Arm Description

Concomitant salpingectomy at the time of hysterectomy for a benign reason

No salpingectomy at the time of hysterectomy for a benign reason

Outcomes

Primary Outcome Measures

Surgical complication - short term primary outcome
Dichotomous outcome, retrieved from any of two sources in the GynOp register: specified question on complications and the Clavien-Dindo classification
Change in menopausal symptom score - intermediate term primary outcome
Measured from baseline to one year follow-up, assessed with Menopause Rating Scale (MRS)
Epithelial ovarian cancer - long term primary outcome
The outcome is dichotomous, the diagnosis is classified according to ICD10. Each case with a positive outcome is further described with histopathological types and grade, as well as clinical stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers

Secondary Outcome Measures

Operative time
Continous outcome, registered in minutes
Length of hospital stay
Continous outcome, registered in days
Perioperative blood loss
Continous outcome, registered in ml
Conversion to other surgical route
Dichotomous outcome
Failure rate of salpingectomy at planned vaginal hysterectomy
Dichotomous outcome
Prevalence of menopausal symptoms of at least moderate level according to Menopause Rating Scale (MRS)
Dichotomous outcome based on MRS
Ovarian function, measured as change in anti-Müllerian hormone (AMH) serum level, from baseline
Continous outcome, measured in mg/L
Subsequent adnexal surgery, including all surgery engaging salpinges and/or ovaries
Dichotomous outcome, accompanied by a description of number and types of surgery performed
Use of Hormone Replacement Therapy (HRT)
Dichotomous outcome
Cardiovascular disease
Dichotomous outcome, accompanied by the specific ICD diagnoses
Fractures (primarily radial, vertebral and hip fractures)
Dichotomous outcome, accompanied by the specific ICD diagnoses

Full Information

First Posted
January 16, 2017
Last Updated
April 3, 2023
Sponsor
Göteborg University
Collaborators
Vastra Gotaland Region, Umeå University
search

1. Study Identification

Unique Protocol Identification Number
NCT03045965
Brief Title
Hysterectomy and OPPortunistic SAlpingectomy
Acronym
HOPPSA
Official Title
Hysterectomy and Opportunistic Salpingectomy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2017 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
December 2053 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Göteborg University
Collaborators
Vastra Gotaland Region, Umeå University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
HOPPSA is a register based randomized controlled trial (R-RCT), with the objective to examine if opportunistic salpingectomy compared with no salpingectomy, at the time of hysterectomy for a benign reason has no increased risk of complications has no negative side effects on ovarian function and subsequent cardiovascular disease or incidence of fractures implies reduced risk of subsequent ovarian cancer Randomization and follow-up will be conducted within national registers.
Detailed Description
High grade serous ovarian cancer, the most fatal subtype, may originate in the fimbriae of the Fallopian tubes. This theory has led to the idea of opportunistic salpingectomy as a way of decreasing the risk of epithelial ovarian cancer (EOC). HOPPSA is a national register-based RCT, with randomization and follow-up in The Swedish National Quality Register of Gynecological Surgery (Gyn/Op). HOPPSA aims to study if opportunistic salpingectomy is safe, and if it can reduce the risk of EOC. PICO P (patients). Women <55 years, undergoing hysterectomy due to a benign reason I (intervention). Bilateral salpingectomy at the time of hysterectomy C (comparison). No salpingectomy O (outcomes). Primary short term: surgical complications reported according to Clavien-Dindo at 8 weeks post-operatively Intermediate term: change in menopausal symptoms from baseline to 1 year, assessed with Menopause Rating Scale Long term: ovarian cancer assessed through the National Cancer Register Recruitment of 4400 patients is estimated to take 4-6 years depending on the participation rate of the Swedish gynecological clinics. Data retrieval from GynOp on short and intermediate term outcomes, requiring smaller sample sizes, will be done at the end of the recruitment period. If these results, ready available when the study recruitment is closed, show that opportunistic salpingectomy does not increase surgical complications and menopausal symptoms, women can be advised to undergo salpingectomy to potentially minimize the future risk of EOC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer, Complication
Keywords
Salpingectomy, Hysterectomy, Ovarian cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Masking of the intervention is planned to include the one-year follow-up of menopausal symptoms.
Allocation
Randomized
Enrollment
4400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Salpingectomy
Arm Type
Experimental
Arm Description
Concomitant salpingectomy at the time of hysterectomy for a benign reason
Arm Title
No salpingectomy
Arm Type
No Intervention
Arm Description
No salpingectomy at the time of hysterectomy for a benign reason
Intervention Type
Procedure
Intervention Name(s)
Salpingectomy
Intervention Description
The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
Primary Outcome Measure Information:
Title
Surgical complication - short term primary outcome
Description
Dichotomous outcome, retrieved from any of two sources in the GynOp register: specified question on complications and the Clavien-Dindo classification
Time Frame
Eight weeks post-operative
Title
Change in menopausal symptom score - intermediate term primary outcome
Description
Measured from baseline to one year follow-up, assessed with Menopause Rating Scale (MRS)
Time Frame
One year after surgery
Title
Epithelial ovarian cancer - long term primary outcome
Description
The outcome is dichotomous, the diagnosis is classified according to ICD10. Each case with a positive outcome is further described with histopathological types and grade, as well as clinical stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers stage according to International Federation of Gynecology and Obstetrics (FIGO). Assessed through national registers
Time Frame
10-30 years after surgery
Secondary Outcome Measure Information:
Title
Operative time
Description
Continous outcome, registered in minutes
Time Frame
At day of surgery
Title
Length of hospital stay
Description
Continous outcome, registered in days
Time Frame
Assessment will be done at discharge from hospital after surgery, including a period up to 8 weeks. a
Title
Perioperative blood loss
Description
Continous outcome, registered in ml
Time Frame
At day of surgery
Title
Conversion to other surgical route
Description
Dichotomous outcome
Time Frame
At day of surgery
Title
Failure rate of salpingectomy at planned vaginal hysterectomy
Description
Dichotomous outcome
Time Frame
At day of surgery
Title
Prevalence of menopausal symptoms of at least moderate level according to Menopause Rating Scale (MRS)
Description
Dichotomous outcome based on MRS
Time Frame
One and five years after surgery
Title
Ovarian function, measured as change in anti-Müllerian hormone (AMH) serum level, from baseline
Description
Continous outcome, measured in mg/L
Time Frame
One year after surgery
Title
Subsequent adnexal surgery, including all surgery engaging salpinges and/or ovaries
Description
Dichotomous outcome, accompanied by a description of number and types of surgery performed
Time Frame
At one and up to ten years after surgery
Title
Use of Hormone Replacement Therapy (HRT)
Description
Dichotomous outcome
Time Frame
At one and up to ten years after surgery
Title
Cardiovascular disease
Description
Dichotomous outcome, accompanied by the specific ICD diagnoses
Time Frame
10-30 years after surgery
Title
Fractures (primarily radial, vertebral and hip fractures)
Description
Dichotomous outcome, accompanied by the specific ICD diagnoses
Time Frame
10-30 years after surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
54 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Planned hysterectomy for a benign reason Age < 55 years at randomization Willing to be randomized Vaginal route may be included if the surgeon is confident with performing vaginal salpingectomy. Exclusion Criteria: Previous bilateral oophorectomy and/or salpingectomy Planned oophorectomy and/or salpingectomy (for reasons such as already diagnosed adnexal tumor, known carrier of the breast cancer susceptibility gene (BRCA) 1/2 mutation or Lynch syndrome (hereditary nonpolyposis colorectal cancer)) Non-understanding of the oral or written study information
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Annika Strandell, PI
Phone
+46 700904454
Email
annika.strandell@vgregion.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Annika Strandell
Organizational Affiliation
Sahlgrenska University Hospital, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sahlgrenska University Hospital
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annika Strandell
Phone
700904454
Email
annika.strandell@vgregion.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Hysterectomy and OPPortunistic SAlpingectomy

We'll reach out to this number within 24 hrs